Use of Infliximab or Adalimumab in Biologic-Naive Patients With Inflammatory Bowel Disease: Study of Patient Reported Outcomes in IBD Partners

被引：0
|
作者：
Weaver, Kimberly [1 ]
Curtis, Jeffrey [2 ]
Beukelman, Tim [2 ]
Zhang, Xian [1 ]
Kappelman, Michael [1 ]
Long, Millie [1 ]
机构：
[1] Univ N Carolina, Chapel Hill, NC 27515 USA
[2] Univ Alabama Birmingham, Birmingham, AL USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2019年 / 114卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P105
引用
收藏
页码：S27 / S28
页数：2
相关论文
共 50 条
  • [21] The Effect of Infliximab and Adalimumab Treatment on Angiogenic Factor Levels in Patients With Inflammatory Bowel Disease (IBD)
    Algaba, Alicia
    Linares, Pablo M.
    Contreras, Maria Encarnacion Fernandez
    Figuerola, Ariadna
    Calvet, Xavier
    Guerra, Ivan
    Villa, Jose Carlos
    Chaparro, Maria
    Agullo, Jose Luis Rodriguez
    Gisbert, Javier P.
    Bermejo, Fernando
    GASTROENTEROLOGY, 2012, 142 (05) : S869 - S870
  • [22] Comparison of Real-World Outcomes of Infliximab versus Adalimumab in Biologic-Naive Korean Patients with Ulcerative Colitis: A Population-Based Study
    Han, Minkyung
    Jung, Yoon Suk
    Cheon, Jae Hee
    Park, Sohee
    YONSEI MEDICAL JOURNAL, 2020, 61 (01) : 48 - 55
  • [23] Rapid Response to Vedolizumab Therapy in Biologic-Naive Patients With Inflammatory Bowel Diseases
    Feagan, Brian G.
    Lasch, Karen
    Lissoos, Trevor
    Cao, Charlie
    Wojtowicz, Abigail M.
    Khalid, Javaria Mona
    Colombel, Jean-Frederic
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2019, 17 (01) : 130 - +
  • [24] Pulmonary Histoplasmosis in a Patient With Inflammatory Bowel Disease (IBD) on Infliximab
    Verdone, J. E.
    Pickering, E.
    Sachdeva, A.
    Nasim, F.
    Holden, V. K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [25] Prevalence and Impact of Inflammatory Bowel Disease-Irritable Bowel Syndrome (IBD-IBS) on Patient Reported Outcomes in CCFA Partners
    Abdallah, Maisa
    Sandler, Robert
    Kappelman, Michael
    Martin, Christopher
    Chen, Wenli
    Anton, Kristen
    Long, Millie
    INFLAMMATORY BOWEL DISEASES, 2016, 22 : S15 - S16
  • [26] Comparison of infliximab with adalimumab in biologic-naive patients with Crohn's disease: a single-center 13-year experience
    Erdogan, C.
    Durak, M. B.
    Alkan, A.
    Kilic, V.
    Kivrakoglu, F.
    Kosar, K.
    Yuksel, I.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2023, 27 (12) : 5757 - 5766
  • [27] Comparative Outcomes of Adalimumab and Infliximab Dose Escalation in Inflammatory Bowel Disease Patients Failing First-Line Biologic Treatment
    Atay, Ali
    Cagir, Yavuz
    Ergul, Mucahit
    Ozturk, Oguz
    Durak, Muhammed Bahaddin
    Yuksel, Ilhami
    JOURNAL OF CLINICAL MEDICINE, 2025, 14 (04)
  • [28] Comparative outcomes of Adalimumab and Infliximab dose escalation in Inflammatory Bowel Disease patients failing first-line biologic treatment
    Atay, A.
    Cagir, Y.
    Ergul, M.
    Ozturk, O.
    Durak, M. B.
    Yuksel, I
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1775 - i1775
  • [29] Cytomegalovirus Colitis Is Rarely Observed After Initiation of Infliximab, Adalimumab, or Vedolizumab in Biologic-Naive Patients With Ulcerative Colitis
    Dalal, Rahul S.
    McClure, Emma L.
    Pruce, Jordan C.
    Allegretti, Jessica R.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S334 - S335
  • [30] Comparative Long-Term Drug Survival of Vedolizumab, Adalimumab, and Infliximab in Biologic-Naive Patients with Ulcerative Colitis
    Dalal, Rahul S.
    McClure, Emma L.
    Marcus, Jenna
    Allegretti, Jessica R.
    DIGESTIVE DISEASES AND SCIENCES, 2023, 68 (01) : 223 - 232
12345